レバミゾールを用いた胃癌免疫化学療法の効果-術後4年生存率について-

DOI Web Site

書誌事項

タイトル別名
  • EFFECT OF IMMUNOCHEMOTHERAPY WITH LEVAMISOLE ON GASTRIC CANCER PATIENTS

抄録

To 84 gastric cancer patients levanisole (LMS) was given starting three days before gastrectomy, at a doses of 150mg/day for three consecutive days every other week for as long as possible. And the survival rates of LMS group were compared with those of the historical control group. In the stage III gastric cancer patients the back ground factors of the both groups were matched as closely as possible. Both groups were concomitantly treated with mitomycin C and FT-207.<br> The survival rate of the LMS group was significantly higher than that of the control group (p<0.05). In the stage III gastric cancer patients the survival rates of the LMS group were significantly higher than those of the control group (p<0.05) when curative resection was performed, the tumor had a diameter of 4.0-8.0cm, there were metastases within the regional lymph nodes (n1), cancer cells infiltrated to the gastric serosa (se), cancer cells were not involved in the venous channels (V0) and they were slightly involved in the lymphatic channels (ly1).

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ